Bharat Biotech submits documents for Covaxin emergency use listing to WHO

Published On 2021-07-13 04:15 GMT   |   Update On 2021-07-13 08:17 GMT

New Delhi: Bharat Biotech on Monday said it has submitted all documents required for the emergency use listing (EUL) of its COVID-19 vaccine Covaxin to the World Health Organization and expects a nod at the earliest.

Last week, World Health Organization (WHO) chief scientist Soumya Swaminathan had said that the global health body is likely to take a decision on Bharat Biotech's COVID-19 vaccine Covaxin in the emergency use listing within four to six weeks.

Advertisement
"All documents required for Emergency Use Listing (EUL) of Covaxin have been submitted to WHO as of 9th July. The review process has now commenced with the expectation that we will receive EUL from WHO at the earliest," Bharat Biotech International Ltd Chairman and MD Krishna Ella said in a tweet posted by the company.
According to WHO guidelines, EUL is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies.
"We currently have six vaccines approved with EUL and have recommendations from our Strategic Advisory Group of Experts (SAGE). We continue to look at Covaxin. Bharat Biotech has now started uploading their data on our portal and that is the next vaccine that will be reviewed by our experts committee," Swaminathan had said.



Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News